Perioperative therapy for HER2-negative stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment given before and after surgery for a rare type of stomach cancer called hepatoid adenocarcinoma. It aims to improve outcomes for patients whose tumors are HER2-negative and have not spread too far.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of hepatoid adenocarcinoma of the stomach.
- Your tumor must be HER2-negative (score of 0 on the test).
- Your cancer must be at stage II or III.
- You need to be healthy enough to have surgery and the treatment before and after it.
- Your performance status (ECOG) must be 0 or 1, meaning you can manage daily activities.
- You cannot have other active cancers (except for very low-risk types like certain skin or thyroid cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan given before and after surgery for a rare type of stomach cancer called hepatoid adenocarcinoma. It's for people whose tumors have a specific HER2 protein marker and are at an early enough stage that surgery is still possible.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
This trial tests a combination of two targeted drugs, with or without chemotherapy, given before and after surgery for stomach or gastroesophageal junction cancer. It aims to improve the chance of curing the cancer by shrinking it before surgery and controlling any remaining cancer after surgery.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a combination of immunotherapy (serplulimab), a targeted HER2 therapy (trastuzumab), and chemotherapy (SOX) after stomach cancer surgery. The goal is to see if this combination reduces the chance of cancer returning in people with HER2-positive stomach cancer.
Hear when a new Hepatoid Adenocarcinoma of Stomach trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.